Home / Resource Library / A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study

A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study

Study investigated the long term outcomes of ibrutinib in CLL.